1933 Industries, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian George Farrell
- Full Time Employees
- 85
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- 1055 West Hastings Street Vancouver BC Canada V6E 2E9
- IPO Date
- Jul 25, 2008
- Website
- 1933industries.com
- Similar Companies
- Business
- 1933 Industries Inc. (CSE:TGIF) is a vertically integrated cannabis company focused on the cultivation, extraction, manufacturing, and wholesale distribution of consumer-branded cannabis and hemp-derived products primarily in Nevada; its core offerings include AMA-branded craft-style flower, infused pre-rolls, full-spectrum oils, high-quality distillates, vaporizer products, and boutique concentrates such as shatter, crumble, batter, sauce, sugar, cured resin, and live resin; as well as Level X branded products; and Canna Hemp wellness line featuring CBD, CBG, and CBN-infused tinctures, topicals, vaporizers, gummies, capsules, functional mushrooms, pet products, and effects-targeted formulations for sleep, relief, calm, focus, energy, sports recovery, and skin care. Founded in 2008 and headquartered in Vancouver, Canada, the company operates through wholly-owned U.S. subsidiaries Alternative Medicine Association LC (AMA), which manages a 68,000 square foot licensed indoor cultivation and production facility in Las Vegas servicing medical and adult-use markets, and Infused MFG LLC, which produces hemp-infused consumer packaged goods; all revenues derive from U.S. operations with AMA products consistently ranking among Nevada's top sellers in dispensaries. In June 2025, 1933 Industries completed the acquisition of the remaining 9% membership interest in AMA from a related party for USD 50,000 via share issuance, achieving 100% ownership through its subsidiary FN Pharmaceuticals and consolidating full control of its primary cultivation asset; the company also reported record annual revenues of $19.3 million for fiscal 2024 ended July 31, reflecting sustained growth in its Nevada wholesale market position.
Company News
1933 Industries Reports Third Quarter 2026 Financial Results
1933 Industries Reports Second Quarter 2026 Financial Results
1933 Industries Provides Update on 2024 Debenture Conversions
1933 Industries Issues Final Reminder to 2024 Debenture Holders: December 22 Is the Deadline to Convert
1933 Industries Achieves Positive Income in Q1 2026, Marking Third Consecutive Profitable Quarter
1933 Industries Issues Reminder to Debenture Holders Ahead of December 22 Conversion Deadline and Highlights Positive Industry Developments
1933 Industries Announces Maturity of Unsecured Convertible Debentures and Encourages Conversion to Support Continued Growth
1933 Industries Announces Year End 2025 Financial Results and Reports Positive Income
1933 Industries Announces Repurchase and Cancellation of Convertible Debentures
1933 Industries Reminds Shareholders to Vote at the Upcoming Annual General Meeting
Ross & Co. Closes Restaurant In Hatboro
1933 Industries Reports Profit in Third Quarter 2025 Financial Results
1933 Industries Announces the Completion of the Purchase of 9% Interest of Cultivation and Production Subsidiary
1933 Industries To Complete Purchase of 9% Interest of Cultivation and Production Subsidiary
1933 Industries Reports Second Quarter 2025 Financial Results
CSE Bulletin: Reinstatement - 1933 Industries Inc. (TGIF)
1933 Industries Announces First Quarter 2025 Financial Report
1933 Industries Announces Fourth Quarter and 2024 Year-End Financial Results with Record Revenues of $19.3 Million
1933 Industries Appoints New CFO and VP Finance
1933 Industries Provides Update on Status of Filing Delay for 4th Quarterly Report